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A 29-year-old man with no history of diabetes ingested over 60 grams of metformin in a suicide 
attempt. He presented to the emergency department with acute renal insufficiency, severe lactic 
acidosis, and rapidly-progressive hyperglycemia. The patient’s peak serum glucose level of 707 mg/
dL is the highest yet reported in a case of metformin toxicity. Treatment included sodium bicarbonate 
infusion and hemodialysis, but the patient suffered several cardiac arrests with pulseless electrical 
activity and ultimately expired 25 hours after the ingestion.
[WestJEM. 2008;9:160-164.]
attempt. The patient consumed the entire remaining contents 
of his father’s prescription metformin bottle that originally 
contained 100 tablets of 850 mg each. The father stated that 
the bottle had contained at least three-quarters of its original 
contents, putting the ingested dose between 64 and 85 grams. 
The patient also consumed ethanol, but denied any other co-
ingestants. The parents discovered the overdose around 6:30 
a.m., about 5½ hours post-ingestion, when the patient began 
complaining of vomiting, diarrhea, thirst, abdominal pain 
and bilateral leg pain. Paramedics were called, who found the 
patient to be agitated with a fingerstick glucose level of 180 
mg/dL.
The patient had a history of psychosis and depression, 
including prior suicide attempts by drug ingestion. He was 
not taking any prescribed medications, having discontinued 
olanzapine and sertraline several months earlier. The patient 
had no personal history of diabetes, despite the family history 
of type II diabetes in his father, who was taking no other anti-
diabetic medications than metformin. The patient admitted 
to daily ethanol and tobacco use, but denied any current or 
past use of illicit drugs. He had no surgical history or known 
allergies.
Vital signs on arrival to the Emergency Department (ED) 
were temperature of 35.2°C (rectal), pulse of 113 beats/min, 
blood pressure of 129/59 mmHg, respirations at 28 breaths/
min with 100% saturation via pulse oximetry on room air. 
The patient was awake and oriented x4, but agitated and 
slightly confused (GCS=14). Pupils were equal and reactive 
INTRODUCTION
Metformin is a biguanide anti-hyperglycemic drug which 
is the most commonly prescribed oral agent to treat diabetes 
mellitus.1 Metformin-associated lactic acidosis (MALA) 
occurs infrequently with therapeutic use, occurring in 0.03 
cases per 1000 patient-years.2 This rate is substantially lower 
than the incidence of phenformin-associated lactic acidosis, 
which caused that biguanide drug to be withdrawn from 
the U.S. market in the late 1970s.2-4 In overdose situations, 
however, metformin is frequently associated with lactic 
acidosis.3,5-15
Because the biguanide drugs do not enhance insulin 
release, as occurs with the sulfonylurea and meglitinide 
classes of diabetes medications, disorders of glucose 
homeostasis are rare with metformin. Although hypoglycemia 
associated with metformin has been reported, it is uncommon 
and often ascribed to concurrent use of other diabetes 
drugs.3,14,16 Hyperglycemia associated with metformin toxicity 
is even more rare, and has previously been ascribed to the 
patients’ underlying diabetes or to acute pancreatitis.3,14,17,18 
We report the case of an intentional overdose of metformin 
in a patient without diabetes which resulted in progressive 
hyperglycemia early in the clinical course and fatal lactic 
acidosis. This patient’s peak serum glucose level of 707 mg/
dL is the highest reported in a case of metformin toxicity.
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at 4mm and the oral mucous membranes were dry. Other than 
tachycardia, the heart and lung exams were unremarkable. The 
abdomen was mildly tender to palpation diffusely, but soft and 
without guarding or rebound. The patient had been incontinent 
of feces prior to arrival, but the stool was guaiac-negative 
and the patient had normal rectal tone. Electrocardiographic 
monitoring demonstrated a narrow-complex sinus tachycardia. 
A repeat fingerstick glucose upon arrival to the ED was 
364 mg/dL. The patient became increasingly combative, 
attempting to bite and spit at the ED staff. He was placed 
in 4-point soft restraints, had a respiratory protection mask 
placed over his mouth, and was medicated with intravenous 
lorazepam 2 mg, dolasetron 12.5 mg, morphine sulfate 4 mg, 
and hydration with 0.9% saline. Within 45 minutes, the patient 
was no longer combative, and the physical restraints were 
removed.
Laboratory evaluation from blood samples obtained 
about one-half hour after ED arrival are shown in Table 
1. Notably, the serum glucose level was 707 mg/dL 
associated with an elevated anion-gap metabolic acidosis. 
Arterial blood gas analysis showed: pH 7.10, pCO2 18.8 
mmHg, and pO2 133.1 mmHg. The serum lactate level 
was above our clinical laboratory’s reporting range (>11.1 
mmol/L). Even accounting for ethanol’s contribution to total 
osmolality, the calculated osmolal gap was highly elevated 
at >20 mOsm/kg. Given the presence of hyperglycemia 
with severe metabolic acidosis, the possibility of diabetic 
ketoacidosis was briefly considered; however, the serum 
β-hydroxybutyrate level was within normal limits (2.4 mg/
Table 1. Initial Laboratory Evaluation (½ hour after ED arrival)
Sodium 136 mEq/L
Potassium 3.1 mEq/L
Chloride 105 mEq/L
Bicarbonate 9 mEq/L
BUN 2 mg/dL
Creatinine 2.1 mg/dL
Glucose 707 mg/dL
Calcium 9.4 mg/dL
Total Protein 7.6 g/dL
AST 60 IU/L
ALT 53 IU/L
Bilirubin 0.8 mg/dL
Acetaminophen <5 μg/mL
Salicylate <4 mg/dL
Lactate >11.1 mmol/L
Ethanol 214 mg/dL
Osmolality 392 mOsm/kg
β-hydroxybutyrate 2.4 mg/dL
dL [0.5-3.0]) and ketonuria was absent. Urinalysis showed 
glycosuria and moderate hemoglobin, but no calcium oxalate 
crystalluria, blood cells, or signs of infection. A urine drug 
screen by enzyme-multiplied immunoassay technique was 
negative for opiates, cocaine, phencyclidine, amphetamines, 
propoxyphene, benzodiazepines, barbiturates, and 
methylenedioxymethamphetamine. 
The patient was admitted to the medical intensive care 
unit service. Due to lack of ICU bed availability, the patient 
physically remained in the ED for several more hours. The 
nephrology service was initially contacted one hour after the 
patient’s arrival for consideration of emergent hemodialysis.
Repeat laboratory analysis on serum samples obtained 
four hours after ED arrival showed decreasing bicarbonate (6 
mEq/L) and continued severe hyperglycemia (672 mg/dL), 
despite continued IV hydration with 0.9% saline boluses. The 
nephrology fellow was at the bedside discussing the benefits 
and risks of dialysis, when the patient was witnessed to 
become unresponsive, vomit, aspirate, and go into pulseless 
electrical activity (PEA) with a heart rate of 29/min. The 
patient was resuscitated with chest compressions, endotracheal 
intubation, 2 mg IV epinephrine, 1 mg IV atropine, and 4 
ampules (176 mEq) of 8.4% sodium bicarbonate, resulting in 
a heart rate of 110/min and blood pressure 121/88 mmHg. An 
intra-resuscitative ABG showed: pH 6.95, pCO2 55.7 mmHg, 
pO2 88.1 mmHg, and bicarbonate 12.4 mEq/L. The patient 
was started on a bicarbonate drip (150 mEq NaHCO3 in 1L 
5% dextrose at 200 cc/hr) and transferred to the ICU.
The patient developed non-sustained episodes of 
ventricular tachycardia, and then his blood pressure fell to 
72/44 mmHg. A dopamine drip was started, but by the time 
the blood pressure stabilized the patient was found to be 
coagulopathic (INR 3.08; fibrinogen 113 mg/dL [156-400]; 
d-dimer >8.0 mcg/mL [<0.5]) and insertion of a hemodialysis 
catheter was delayed until the patient was treated with four 
units of fresh frozen plasma. The concurrent platelet count was 
390 k/mm3 and the hematocrit was 47.7%. An echocardiogram 
showed mildly decreased left ventricular function, although 
serial cardiac enzymes showed progressive elevation of the 
CK-MB fraction and troponin I (up to 1.321 ng/mL [<0.03]). 
Hemodialysis was begun twelve hours after ED arrival. 
Three hours later, the patient again developed PEA and was 
resuscitated. Several more episodes of PEA recurred, and the 
patient expired about 19 hours after ED arrival. The last set of 
laboratory results, drawn five hours prior to death, showed a 
serum lactate level still >11.1 mEq/L, bicarbonate 12 mEq/L, 
and glucose 327 mg/dL. The hyperglycemia persisted despite 
treatment with an insulin drip (3 units regular insulin/hr) 
and the hemodialysis. No measurements of serum lipase or 
amylase were made during the patient’s hospitalization.
DISCUSSION
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but may have serious consequences. In a five-year review of 
toxic exposures reported to U.S. poison control centers, only 
4072 out of nearly 11 million exposures involved metformin, 
corresponding to less than one in 2500.3 There were a total 
of 9 deaths (0.2% of all metformin-related exposures), 32 
cases with life-threatening signs or symptoms and/or residual 
disability (0.8%), and 187 cases with moderate clinical 
effects (4.6%). Cases of serious toxicity from metformin 
overdose are rare enough that single case reports and small 
case series continue to be published, which often describe 
extracorporeal methods of managing the consequent severe 
lactic acidosis.5-13,15
Lactic acidosis may occur either with therapeutic 
metformin dosing or in overdose; 0.03 cases of lactic acidosis 
per 1000 patient-years occur with therapeutic dosing, 
and most of these cases occur among patients who have 
contraindications to metformin, such as renal insufficiency.2 
In overdose situations, lactic acidosis is seen much more 
commonly, although the exact incidence is unclear. Lactic 
acidosis was seen in 1.6% of metformin exposures reported 
to poison control centers, but only 10% of these exposures 
were due to intentional overdoses.3 In a review of poison 
control center inquiries from Germany, the incidence of 
metformin-associated lactic acidosis was 12.8% (14 of 109 
calls); however, the incidence of attempted suicide was 
56.9% in this group, suggesting that higher metformin doses 
were involved.11 Case reports and series of severe toxicity 
from metformin are typically associated with severe lactic 
acidosis,5-13,15,17,18 and many of these are due to intentional 
overdose.5-10,12,13,15,18 Such publications, however, form an 
obviously biased group, and the actual incidence of lactic 
acidosis with intentional metformin overdose remains 
unknown.
The prognosis in cases of undifferentiated lactic acidosis 
is poor, with an expected case-fatality rate of 30-50%.2,19 
In cases of metformin-associated lactic acidosis, the serum 
lactate level does not correlate with prognosis, even with 
lactate levels as high as 35.5 mmol/L.19 In cases where 
metformin levels have been measured, there is a poorer 
prognosis with lower metformin levels.19 This unusual 
finding suggests that patients developing lactic acidosis at 
lower metformin levels probably have concurrent underlying 
disease, placing them at higher risk both for accumulating 
lactate and for death.
The most striking feature of the case reported here, 
however, is the profound and progressive hyperglycemia, 
which has not been previously reported. Metformin generally 
does not cause significant alterations in serum glucose 
levels, even in overdose situations. Unlike the sulfonylurea 
and meglitinide classes of diabetes drugs, which stimulate 
insulin release from the pancreas and therefore lower the 
glucose level, the biguanide drugs have more complex effects 
on glucose homeostasis that tend to reduce hyperglycemia 
without inducing hypoglycemia. These effects include: 
inhibition of hepatic gluconeogenesis (primarily through 
inhibiting hepatic lactate uptake), improving peripheral 
insulin sensitivity, inhibition of fatty acid oxidation, and 
possibly reducing intestinal glucose absorption.2,19 Metformin 
also increases production of lactate by the intestinal mucosa 
and suppresses pyruvate carboxylase, which impairs lactate 
clearance. Thus, lactic acidosis may occur in patients 
who have overdosed on metformin, or those with renal 
insufficiency, whose lactate clearance is already impaired.
Although metformin does not directly lower glucose 
levels, metformin-associated hypoglycemia has been reported, 
both with therapeutic dosing and with overdoses.3,14,16 
Hypoglycemia was reported in 2.8% of metformin exposures 
reported to a poison control center.3 In many of these cases the 
patients were receiving concurrent treatment with sulfonylurea 
drugs, which likely contributed in causing hypoglycemia. 
Some instances of drug interactions with metformin have 
been associated with hypoglycemia (e.g, with enalapril, which 
increases insulin sensitivity)20, although hypoglycemia with 
isolated metformin exposure is very rare. 
Hyperglycemia associated with metformin overdose has 
occasionally been reported, but is even less common than 
hypoglycemia. In their review of 4072 metformin exposures, 
Spiller and Quadrani found only 18 cases associated with 
hyperglycemia (versus 112 with hypoglycemia), which they 
attributed as most likely due to the patients’ underlying 
diabetes.3 Nearly 40% of cases with hyperglycemia (seven 
of 18) occurred in patients who died, and seven of the nine 
overall fatalities had hyperglycemia, suggesting that it may be 
associated with particularly severe metformin toxicity.
Hyperglycemia has been related to acute pancreatitis 
in a few cases of metformin toxicity from both intentional 
overdose11,18 and therapeutic dosing.17 In the previously 
published cases of pancreatitis with metformin toxicity, the 
degree of hyperglycemia was considerably lower than in 
our patient: 162 mg/dL17, 345 mg/dL11, and 450 mg/dL (this 
final patient presented with hypoglycemia [23 mg/dL] and 
only became hyperglycemic after treatment with parenteral 
glucose).18 Similarly, our patient’s peak serum glucose 
exceeded the highest level (698 mg/dL) reported among 
diabetic patients taking metformin therapeutically who went 
on to develop lactic acidosis.21 Since our patient did not have 
a history of diabetes, his extreme hyperglycemia is all the 
more unexpected. Also, we could not identify any previously 
published cases where the hyperglycemia progressively 
worsened, in the absence of administration of glucose, as 
occurred in our patient early in his clinical course.
The potential mechanism for the severe hyperglycemia in 
our patient is not clear. Nothing among metformin’s known 
mechanisms would logically explain the progressive and 
severe hyperglycemia, especially since these mechanisms 
should tend to limit the glucose level. However, if one 
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considers what might occur if the patient could no longer 
secrete enough insulin, as may occur with pancreatitis, then a 
potential explanation arises. With a lack of circulating insulin, 
metformin’s ability to enhance peripheral insulin sensitivity 
would count for nothing. Glucose would accumulate in the 
serum, since it would not be able to enter the tissues.  It 
is also possible that a counter-regulatory hormone surge 
(epinephrine ± glucagon) from the acute physiologic 
stress of the overdose contributed to the hyperglycemia. 
This mechanism is conjectural, since pancreatitis was not 
confirmed in our patient with serum amylase and lipase 
levels, nor with any radiographic study showing pancreatic 
inflammation. Similarly, no circulating insulin levels were 
measured, which would have to be low for this mechanism 
to work. Nevertheless, pancreatitis remains a promising 
potential mechanism, as our patient’s clinical presentation 
with complaints of vomiting and abdominal pain is consistent 
with previously reported cases of metformin-associated 
pancreatitis.11,17,18
Alternate toxicologic causes for this patient’s 
hyperglycemia seem unlikely. Only a few toxins are routinely 
associated with hyperglycemia, including calcium channel-
blockers and the ingestion of agents that specifically poison 
pancreatic beta-islet cells, such as alloxan, nitrophenolurea 
(an obsolete rodenticide), and streptozocin (a chemotherapy 
agent for pancreatic islet cell tumors). Calcium channel-
blockers can impair insulin release, often resulting in modest 
hyperglycemia. Our patient had no known access to these 
drugs and did not present with hypotension or bradycardia. 
Similarly, our patient had no known access to beta-islet cell 
poisons, and the resultant hyperglycemia from these agents 
occurs in association diabetic ketoacidosis within a few days 
after significant exposure.
Our patient also ingested ethanol, which may have 
contributed to his severe toxicity. Ethanol itself may have 
increased the serum lactate level or induced pancreatitis. 
Also, the interaction of ethanol with biguanide drugs has been 
shown to increase lactate levels both in animal and human 
studies.4
Another potential complicating factor was the elevated 
osmolal gap in our patient, unaccounted for by the serum 
ethanol level. The presence of a highly elevated osmolal 
gap (>20 mOsm/kg) is most frequently caused by exposure 
to toxic alcohols,22 and our patient had a progressively 
worsening metabolic acidosis, which would be consistent 
with toxic alcohol poisoning. However, our patient denied 
ingesting anything but ethanol and metformin, and his parents 
confirmed that they saw no evidence at home of exposure to 
products containing isopropanol, methanol, or ethylene glycol. 
An unexplained osmolal gap may be seen in several severe 
disease states, including shock or sepsis,22 and was also seen 
in four out of nine cases of fatal metformin toxicity,3 providing 
an alternate explanation for its presence. We believe our 
patient’s severe acidosis and osmolal gap is highly unlikely 
to have occurred from toxic alcohol exposure for several 
reasons. Firstly, there was no historical evidence supporting 
the ingestion of any alcohol other than ethanol. Secondly, the 
patient did not exhibit additional clinical signs of end-organ 
damage, such as visual complaints from methanol toxicity, nor 
calcium oxalate crystalluria from ethylene glycol. The patient 
did have an elevated initial serum creatinine of 2.1 mg/dL, 
but this did not worsen as would be expected from ethylene 
glycol poisoning. Also, he had no ketonuria as would occur 
with isopropanol ingestion. Ingestion of propylene glycol 
might result in presentation with lactic acidosis and renal 
insufficiency, but such exposures are rare and severe acidosis 
should not occur in the presence of a supra-“therapeutic” 
ethanol level. Even if our patient had had severe toxic 
alcohol poisoning, the treatment would have included alcohol 
dehydrogenase inhibition, which was already effected by the 
presence of ethanol, and hemodialysis, which was already 
planned to treat his severe metformin toxicity.
CONCLUSION
Metformin toxicity is associated with development of 
lactic acidosis. Because metformin does not induce insulin 
release by pancreatic beta-islet cells, exposures infrequently 
induce disorders of glucose homeostasis. When abnormal 
glucose levels occur with metformin exposures, hypoglycemia 
is much more commonly seen than hyperglycemia; 
hypoglycemia is usually ascribed to concurrent anti-diabetic 
medications such as the sulfonylureas. Hyperglycemia appears 
to be a marker of severe toxicity in cases of metformin 
poisoning, and may be associated with the patient’s underlying 
diabetes or the development of pancreatitis.
We presented the case of a non-diabetic 29-year-old 
man who took a large overdose of metformin and ethanol in 
a suicide attempt. He presented with severe lactic acidosis 
and a progressively increasing serum glucose level. The 
hyperglycemia might have been due to pancreatitis, although 
confirmatory studies were not obtained before the patient died.   
The patient’s peak serum glucose level of 707 mg/dL is the 
highest yet reported in a case of metformin toxicity.
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